1. Home
  2. Product Information
  3. 5-HT4 Partial Agonist

Product Information

5-HT4 Partial Agonist (RQ-00000010)

Compound Code RQ-00000010
Primary Target Indications Functional GI disorder
Development Stage Phase 1 (UK)
Portfolio for global development, manufacturing, and marketing rights
Product Summary Serotonin 5-HT4 receptor is known to have an important role in improving gastrointestinal motility.  RQ-00000010 has been successfully discovered in RaQualia Pharma as a compound with fewer cardiovascular adverse events associated with the conventional 5-HT4 agonists.  In non-clinical studies, strong pharmacological activity and high safety profiles of RQ-00000010 have been confirmed in animals.  In Phase I clinical trial, its excellent safety/tolerability and pharmacokinetic profiles of RQ-00000010 were also confirmed as expected.  Of note is that the strong efficacy on accelerated gastric emptying has been demonstrated in human as well. Therefore, RQ-00000010 could be a safe and therapeutically-effective drug for functional GI disorder such as gastroparesis and functional dyspepsia as well as chronic constipation and other indications caused by impaired gastrointestinal motility.

Licensing Status

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Press Release
Research & Development
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release